Dr. Jane Apperley CML Chronic Myeloid Leukemia
Professor of Medicine
Chair, Department of Haematology
Division of Investigative Science
Imperial College School of Medicine
Hammersmith Hospital
London, United Kingdom
Chair, Department of Haematology
Division of Investigative Science
Imperial College School of Medicine
Hammersmith Hospital
London, United Kingdom
''Her particular interests are the biology and management of chronic myeloid leukemia, which has led naturally to an extensive experience in stem cell transplantation and more recently, to the use of signal transduction inhibitors in this disease.''
Extract of Background by ReachMD
VIDEOS
Second and third generation TKIs – How should we choose? Must be seen!
October 19, 2019, CML Support Group UK
Highlights from ASH 2018: Prof. Jane Apperley
December 2018, iCMLf
Overview of chronic myeloid leukaemia
September 2, 2015, Bloodwise
Who gets CML?
September 2, 2015, Bloodwise
EHA19 CML Colloquium: The Stem Cell Transplant Story
June 2014, iCMLf
Second and third generation TKIs – How should we choose? Must be seen!
October 19, 2019, CML Support Group UK
Highlights from ASH 2018: Prof. Jane Apperley
December 2018, iCMLf
Overview of chronic myeloid leukaemia
September 2, 2015, Bloodwise
Who gets CML?
September 2, 2015, Bloodwise
EHA19 CML Colloquium: The Stem Cell Transplant Story
June 2014, iCMLf
ARTICLES
Isabel Cunningham Holds CML Question-and-Answer Session With Jane Apperley, MD
February 24, 2016, Cancer Therapy Advisor
Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy
August 18, 2011, Haematologica
OncologyStat -CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
November 23, 2010, CMLSupport
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005
March 13, 2006, Bone Marrow Transplantation
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
July 1, 2000, Journal Blood
Isabel Cunningham Holds CML Question-and-Answer Session With Jane Apperley, MD
February 24, 2016, Cancer Therapy Advisor
Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy
August 18, 2011, Haematologica
OncologyStat -CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
November 23, 2010, CMLSupport
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005
March 13, 2006, Bone Marrow Transplantation
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
July 1, 2000, Journal Blood